VRP.L Regulatory News (VRP)

Verona Pharmaplc ("Verona Pharma" or the "Company") Director's Dealing 14 January 2015, Cardiff - Verona Pharma plc (AIM: VRP) yesterday receivednotification that on 13 January 2015, Dr. David Ebsworth, Non-ExecutiveChairman of the Company, purchased 803,107 ordinary shares of 0.1p each in theCompany ("Ordinary Shares") at a price of 1.35 pence per share. Following the acquisition, Dr. Ebsworth will have an interest in the Company of2,129,774 Ordinary Shares, representing 0.21% of the Company's issued ordinaryshare capital. -Ends- For further information please contact: Verona Pharma plc Tel: +44 (0) 20 3283 4200Jan-Anders Karlsson, CEO N+1 Singer Tel: +44 (0)20 7496 3000Aubrey Powell / Jen Boorer FTI Consulting Tel: +44 (0)20 3727 1000Julia Phillips / Simon Conway Notes to Editors About Verona Pharma plc Verona Pharma plc is a UK-based clinical stage biopharmaceutical companyfocused on the development of innovative prescription medicines to treatrespiratory diseases with significant unmet medical needs, such as COPD, asthmaand cystic fibrosis. Verona Pharma's lead drug, RPL554, is a first-in-classdrug currently in Phase II trials as a nebulised treatment for acuteexacerbations of COPD in the hospital setting. The drug is adual phosphodiesterase (PDE) 3/4 inhibitor and therefore has bothbronchodilator and anti-inflammatory effects, which are essential to theimprovement of patients with COPD and asthma. Verona Pharma is also building abroader franchise around RPL554 to maximise its value, both to patients and toinvestors. This includes the very significant markets for COPD and asthmamaintenance therapy. The Company is also exploring the potential of the drug indifferent diseases, such as cystic fibrosis, where it is in pre-clinicaltesting.